Related Experiment Videos
Recalcitrant viral warts treated by diphencyprone immunotherapy
D A Buckley1, F M Keane, S E Munn
1Department of Dermatology, King's College Hospital, Denmark Hill, London SE5 9RS, UK.
The British Journal of Dermatology
|September 1, 1999
Summary
Diphencyprone (DCP) immunotherapy effectively treats stubborn viral warts. Most patients achieved complete wart clearance with this treatment, though some experienced side effects.
Area of Science:
- Dermatology
- Immunology
Background:
- Recalcitrant viral warts present a significant therapeutic challenge.
- Immunotherapy using diphencyprone (DCP), a contact sensitizer, offers a potential solution.
Purpose of the Study:
- To evaluate the efficacy and safety of DCP immunotherapy for resistant hand and foot warts.
- To review an 8-year experience with DCP treatment.
Main Methods:
- Retrospective review of 60 patients sensitized to DCP for recalcitrant warts.
- Analysis of treatment duration, clearance rates, and adverse events.
Main Results:
- 88% (42/48) of patients achieved complete wart clearance.
- Median treatment time was 5 months, with a median of 5 applications.
- 56% experienced adverse effects, commonly local blistering and eczematous reactions.
Conclusions:
- DCP immunotherapy is a highly effective treatment for recalcitrant viral warts.
- Patient motivation and awareness of potential side effects are crucial for successful treatment.
- Long-term follow-up showed no recurrence in treated patients.